Drug Watch

Latest News

AC-201 Shows Strong Phase 2 Results in Psoriasis Trial
AC-201 Shows Strong Phase 2 Results in Psoriasis Trial

May 21st 2025

Accropeutics reveals promising Phase 2 trial results for AC-201, a selective TYK2/JAK1 inhibitor, showing significant efficacy in treating plaque psoriasis.

Expert Insights Highlight Novel ITK Inhibition With Soquelitinib for AD
Expert Insights Highlight Novel ITK Inhibition With Soquelitinib for AD

May 19th 2025

Artax Biopharma's AX-158: A Novel Approach to T Cell-Driven Inflammation in Psoriasis
Artax Biopharma's AX-158: A Novel Approach to T Cell-Driven Inflammation in Psoriasis

May 15th 2025

Artax Presents Phase 2a Results of AX-158 for Plaque Psoriasis
Artax Presents Phase 2a Results of AX-158 for Plaque Psoriasis

May 9th 2025

Corvus Pharmaceuticals’ Soquelitinib Shows Rapid, Dose-Dependent Efficacy in Phase 1 AD Trial
Corvus Pharmaceuticals’ Soquelitinib Shows Rapid, Dose-Dependent Efficacy in Phase 1 AD Trial

May 8th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.